ទំព័រដើម › Non-Small Cell Lung Cancer › អូរេហ្គោន › Portland
ការសាកល្បងគ្លីនិកសម្រាប់ Non-Small Cell Lung Cancer នៅក្នុង Portland, OR
ការសិក្សាចំនួន 46 សម្រាប់ Non-Small Cell Lung Cancer កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Portland (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
កំពុងជ្រើសរើសដំណាក់កាល 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
កំពុងជ្រើសរើសដំណាក់កាល 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · ឆ្ងាយ 12 ម៉ាយ
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Oregon Health & Science University (OHSU), Portland
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Exelixis Clinical Site #51, Portland
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
កំពុងជ្រើសរើសដំណាក់កាល 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Site 02, Portland
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- ALX Center 6, Portland
A Study of PHN-012 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- PHN-012-001 Site, Portland
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site, Portland
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 3
- OHSU Knight Cancer Institute, Northwest, Portland
- Providence Cancer Institute Franz Clinic, Portland
- OHSU Knight Cancer Institute, East Portland, Portland
- និង 6 ទៀត
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Oregon Health and Science University ( Site 0052), Portland
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 2
- Providence Cancer Center, Portland
- Providence Oncology and Hematology Care Clinic Westside, Portland
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Northwest Cancer Specialists, P.C., Portland
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Oregon Health And Science University, Portland
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Oregon Health And Science University, Portland
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site, Portland
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
- និង 1 ទៀត
Pan-tumor MRD Study
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Oregon Health & Science University (OHSU), Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Providence Cancer Institute Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Providence Portland Medical Center, Portland
- Oregon Health and Science University, Portland
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
កំពុងជ្រើសរើសដំណាក់កាល 3
- Clinical Study Site, Portland
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
កំពុងជ្រើសរើសដំណាក់កាល 3
- Providence Cancer Institute, Portland
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Local Institution - 007-885B, Portland
- Local Institution - 007-885A, Portland
A Phase 1/1b Study of IAM1363 in HER2 Cancers
កំពុងជ្រើសរើសដំណាក់កាល 1
- Providence Cancer Institute, Portland
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Oregon Health and Science University, Portland
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Providence Portland Medical Center, Portland
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
កំពុងជ្រើសរើសដំណាក់កាល 3
- Oregon Health & Science University, Portland
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Providence Cancer Institute, Portland
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Compass Oncology - Rose Quarter, Portland
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Providence Cancer Institute, Portland
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- និង 1 ទៀត
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Oregon Health and Science University, Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
កំពុងជ្រើសរើសដំណាក់កាល 4
- OHSU Knight Cancer Institute, Portland
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- និង 2 ទៀត
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- USA15-0, Portland
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- និង 2 ទៀត
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- និង 1 ទៀត
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
កំពុងជ្រើសរើសដំណាក់កាល 2
- Providence Health & Services - Oregon, Portland
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- និង 2 ទៀត
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Kaiser Permanente Northwest, Portland
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Providence Cancer Institute, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massive Bio SYNERGY-AI site, Portland
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Oregon Health & Science University, Portland
ការសាកល្បងសម្រាប់ Non-Small Cell Lung Cancer នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 145
- New York City, NYការសិក្សា 121
- Arlington, VAការសិក្សា 104
- Nashville, TNការសិក្សា 97
- Boston, MAការសិក្សា 90
- Los Angeles, CAការសិក្សា 87
- St. Louis, MOការសិក្សា 73
- Chicago, ILការសិក្សា 61
- Baltimore, MDការសិក្សា 60
- San Antonio, TXការសិក្សា 59
- Columbus, OHការសិក្សា 57
- Washington, DCការសិក្សា 55
ការសិក្សាផ្សេងទៀតនៅក្នុង Portland
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 34
- មហារីកទ្រូងការសិក្សា 33
- មហារីកតូចការសិក្សា 33
- មហារីកដែលរីករាលដាលការសិក្សា 29
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 28
- មហារីកស៊ុតការសិក្សា 27
- មហារីកសួតការសិក្សា 26
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 25
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 24
- មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅកការសិក្សា 19
- មហារីកតំបក់ការសិក្សា 19
- បេះដូងខ្សោយការសិក្សា 17
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។